CN102688261A - Pteris multifida extract, preparation method thereof and use thereof - Google Patents
Pteris multifida extract, preparation method thereof and use thereof Download PDFInfo
- Publication number
- CN102688261A CN102688261A CN2011100669854A CN201110066985A CN102688261A CN 102688261 A CN102688261 A CN 102688261A CN 2011100669854 A CN2011100669854 A CN 2011100669854A CN 201110066985 A CN201110066985 A CN 201110066985A CN 102688261 A CN102688261 A CN 102688261A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba pteridis
- pteridis multifidae
- glucoside
- apigenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pteris multifida extract which is extracted from pteris plants. The pteris multifida extract mainly contains flavonoid ingredients including apigenin-7-O-beta-D-glucose-4'-O-alpha-L-rhamnoside, luteolin-7-O-beta-D-glucoside and the like. The invention also discloses a preparation method of the pteris multifida extract, mainly characterized in that the extract is obtained through processes of ethanol extraction, water precipitation treatment, macroporous resin column purification and the like performed on the pteris plants, wherein the macroporous resin preferably is macroporous resin of weak polarity. The invention further discloses uses of the pteris multifida extract in the fields of medicine and food. The pteris multifida extract is mainly characterized by anti-inflammatory effect, especially anti-prostatitis effect or benign prostatic hyperplasia inhibition effect.
Description
Technical field
The present invention relates to a kind of Herba Pteridis Multifidae extract, the present invention relates to this preparation method of extract and purposes simultaneously.
Background technology
Herba Pteridis Multifidae (Pteris multifida Poir.) is a Pteridaceae Herba Pteridis Multifidae platymiscium, has another name called Gallus jabouillei tail, Herba Pteridis multifidae, ferrum foot chicken etc., is born in dark and damp crag and wall, crack of stone place, extensively distributes in area, temperate zone, the whole world.Chinese medicine is thought Herba Pteridis Multifidae mildly bitter flavor cold in nature; Effect with subduing swelling and detoxicating, clearing away heat-damp and promoting diuresis, cooling blood for hemostasis; Cure mainly dysentery, have loose bowels, stranguria with turbid discharge, leukorrhagia, jaundice, tonsillitis, parotitis, mastitis, haematemesis, epistaxis, hematuria, have blood in stool and disease such as traumatic hemorrhage, clinical practice is in diseases such as treatment infectious hepatitis, acute bacillary dysenteries.Its Main Ingredients and Appearance of modern chemistry research is flavonoid, pterosin type sesquiterpene, Kaurane diterpine etc.; The flavonoid composition of from Herba Pteridis Multifidae, having found comprise apigenin, apigenin-7-O-beta-D-glucoside, apigenin-3 '-O-β-D-glucoside, apigenin-7-O-beta-D-glucose-4 '-O-alpha-L-rhamnoside, luteolin, luteolin-7-O-β-D-glucoside, luteolin-7-O-β-D-glucoside etc. [Sun Haiyan etc. the progress of Chinese medicine Herba Pteridis Multifidae. Chinese veterinary's parasitic disease 2007,15 (3): 422-6].Other Herba Pteridis Multifidae congener effect is similar with chemical analysis; Like Herba Pteridis creticae (Pteris cretica var.nervosa), half Herba Pteridis creticae (Pteris dispar), Herba Pteridis Semipinnatae (Pteris semipinnata) etc.; Detailed ginseng " China's book on Chinese herbal medicine " volume two; Science and Technology of Shanghai publishing house, 1999:115-126.
Herba Pteridis Multifidae is China's characteristic traditional herbal medicine, and pertinent literature concentrates on China.Zhu Dayuan, Xiang Gui etc. (separate plain derivant of foreign celery and their purposes from Herba Pteridis Multifidae; Application number CN200510024554.6) disclose foreign celery in the Herba Pteridis Multifidae plain-4 '-alpha-L-rhamnoside, foreign celery element-4 '-α-L-rhamnose-7-β-D-heteroside, luteolin, Palmic acid and mountain Yu acid has inhibitory action to the prostatic cell proliferation of In vitro culture, can be used for treating in prostate hyperplasia and the prostatitis medicine; This method for preparing of inventing the plain derivant of said foreign celery adopts mainly that 20-40% ethanol extraction, macroporous resin or polyamide column are refining, the process route of different concentration ethanol-water gradient elution, and further adopts silica gel, gel filtration chromatography to obtain said monomer composition; But this invention does not relate to the content and the composition of total flavone of phoenix-tail fern and forms.Liu Jianqun etc. [macroporous resin is to the enrichment research of Herba Pteridis Multifidae water position total flavones. Jiangxi College of Traditional Chinese Medicine journal 2009; 21 (4): 49-51.] adopt 70% ethanol extraction Herba Pteridis Multifidae; Successively with after dividing the position extraction behind petroleum ether, ethyl acetate, the n-butanol extraction; The De Shui position utilizes the LSA40 macroporous resin that the total flavones at Herba Pteridis Multifidae Zhong Shui position is carried out enrichment, and general flavone content is 27%.(the new application of total flavone of phoenix-tail fern such as Xia Yuye; Patent No. CN200610027926.5) disclose a kind of total flavone of phoenix-tail fern and prevented and treated the new application in the ischemic diseases medicine in preparation, this is invented said total flavones and adopts behind 70% ethanol extraction, the defat with petroleum ether water liquid to obtain through steps such as macroporous resin are refining.Huang Yunfeng, Liu Guoling [macroporous resin is to the influence of Herba Pteridis Multifidae flavone adsorbing separation characteristic research. the Guizhou agricultural sciences; 2010; 38 (6): 57-59.] 4 kinds of macroporous adsorbent resin HPD100, HPD600, HPD700, HPD722 and AB-8 are compared; The result shows that the HPD700 resin is suitable for the purification of Herba Pteridis Multifidae flavone, and purified back Herba Pteridis Multifidae flavone purity can reach 51.8%.(a kind of method for distilling of flavonoid compound from bracken such as Zhang Shuxiang; Application number CN200810101749.X) a kind of method of extracting flavone compound in the Herba Pteridis Multifidae medical material is disclosed; The Herba Pteridis Multifidae medical material is behind ethanol extraction, defat with petroleum ether, and with ethyl acetate-n-butanol mixed solvent system extracting and enriching flavone compound, gained extract cream is through alkali extraction and acid precipitation; Promptly get flavone compound, purity can reach more than 60%.In the macroporous resin technology of preparing of existing total flavone of phoenix-tail fern, the total flavones purity of optimizing technology is 51.8%, generally all adopts organic solvent degreasing to handle, and uses but this method is inappropriate for suitability for industrialized production.On the other hand, prior art is formed the composition of total flavone of phoenix-tail fern in the product and is uncertain, thereby is difficult to obtain to form product stable, that process controllability is good in the actual production.
The inventor is in clinical practice; Investigation finds that ground such as Suzhou, granary are among the people has the Herba Pteridis Multifidae of use single herbtherapy prostatic hyperplasia, a prostatitic experience; Thereby during 1999-2006, carried out first clinical verification [Xue Boxin etc. the evaluation of clinical curative effect of Herba Pteridis Multifidae granule treatment benign prostate hyperplasia. Chinese combination of Chinese and Western medicine magazine 2008,28 (5): 456-458; Dan Yuxi etc. single medicinal material Herba Pteridis Multifidae granule treatment chronic prostatitis (III A type) 87 examples. Journal of Traditional Chinese Medicine, 49 (6): 549.].Study through Shanghai Pharmaceutical Inst., Chinese Academy of Sciences; The apigenin that discovery obtains from Herba Pteridis Multifidae-4 '-O-rhamnoside, apigenin-7-O-glucose-4 '-compositions such as O-rhamnoside, mountain Yu acid have strong inhibitory action to the prostatic cell proliferation of cultivating; Be expected to develop into treatment prostatic hyperplasia and prostatitis new drug [Qin Bo; Zhu Dayuan; Xiang Gui etc. the chemical constituent of Herba Pteridis Multifidae and to the epithelial depression effect of external rat prostate. Chinese natural drug 2006,10 (6): 428-431.].Content of the present invention is the follow-up discovery on the early-stage Study basis.
Summary of the invention
The purpose of this invention is to provide that a kind of composition is stable, technology and quality controllable Herba Pteridis Multifidae extract.
Another object of the present invention provides this extract in the food of antiinflammatory action or the application in the medicine.
The method for preparing Herba Pteridis Multifidae extract provided by the invention comprises following processing step:
(1) choose Herba Pteridis Multifidae platymiscium medical material, adopt water or alcohol-water mixed solvent to extract, the simmer down to concentrated solution adds the suitable quantity of water dilution, leaves standstill under the certain way 6-24 hour, filters, and gets Herba Pteridis Multifidae solution;
(2) by (1) gained Herba Pteridis Multifidae solution, adopt the good macroporous resin of pretreatment to adsorb, with washing, reuse alcohol-water mixed solvent is pressed 10-30%, 50-95% ethanol gradient elution earlier, collects 50-95% ethanol elution position eluent, concentrates, and drying promptly gets.
Said processing step (1) Chinese crude drug is selected Herba Pteridis Multifidae platymiscium herb for use, wherein preferred Herba Pteridis Multifidae or have the congener that similar total flavones is formed.Extraction solvent can adopt conventional water or ethanol-water (50-75%) mixed solvent to extract, and extracting solution merges, well-established law concentrate concentrated solution, add the suitable quantity of water dilution again, filter, Herba Pteridis Multifidae solution.For further improving general flavone content in the extracting solution, can preferably adopt a water precipitating to handle, promptly concentrated solution adds suitable quantity of water again and (is 1-5 times of press the medical material dry weight basis; Preferred 1-3 doubly); Leave standstill 6-24 hour (preferred 8-16 hour) under room temperature or the refrigerated condition, refilter, get Herba Pteridis Multifidae solution.
In the said processing step (2), said macroporous resin preferred nonpolar or low pole macroporous resin, more preferably low pole macroporous resin.During the macroporous resin column gradient elution more preferably by 10-30%, 60-75% ethanol gradient elution and collect 60-75% ethanol elution position eluent and obtain Herba Pteridis Multifidae extract.Mainly contain the flavonoid composition in the said extract, wherein Main Ingredients and Appearance apigenin-7-O-beta-D-glucose-4 '-total content of O-alpha-L-rhamnoside and luteolin-7-O-β-D-glucoside is greater than 20%.Also contain in this extract luteolin-7-O-β-D-glucoside, apigenin-7-O-beta-D-glucoside, apigenin-3 '-more than at least a in the composition such as O-β-D-glucoside, apigenin, luteolin.Adopt sodium nitrite-aluminum chloride colorimetry, rutin contrast, record general flavone content average out to 58% in the said extract.
The present invention adopts preferred macroporous resin to carry out the selectivity gradient elution through the Herba Pteridis Multifidae extract technical study, and in conjunction with the water precipitating treatment process, general flavone content is greater than 55% in the acquisition extract; Simultaneously clear and definite main two kinds of index sexual element and total content thereof in this extract are for its quality control provides reference frame.This production technology has reduced the purification cost, easy realization of industrial production, and environmentally safe.
Connecting the gland proliferative effect before the present invention's antiinflammatory, resistance prostatitis and inhibition to this extract simultaneously investigates.Result of study: the acute ear swelling result of the test of (1) mice caused by dimethylbenzene xylene shows that said extract perfusion administration (500mg/kg) has certain antiinflammatory action; (2) DPT vaccine causes mice prostatitis test and shows; (lymphocyte, the plasma cell that soak in 12g crude drug/kg), the former prostatitis of Herba Pteridis Multifidae extract group (300mg/kg, the 150mg/kg) sex organization all reduce Herba Pteridis Multifidae ethanol extract group, show that Herba Pteridis Multifidae extract has the resistance prostatitis effect; (3) Testosterone Propionate causes mice prostatic hyperplasia test and shows, Herba Pteridis Multifidae ethanol extract group (12g crude drug/kg), Herba Pteridis Multifidae extract group (300mg/kg, 150mg/kg), the administration of proscar matched group after 30 days the pathology section examination prostatic hyperplasia alleviate.The result shows, said extract have preferably anti-inflammatory activity, resistance prostatitis and anti-before connect the gland proliferative effect, can be applied in different functions food and the medicine according to the use needs.
Content of the present invention through lot of experiments, carry out the process optimization analysis and accomplish, describe with following specific embodiment.
Description of drawings
Accompanying drawing is the liquid chromatogram (detecting wavelength 340nm) of Herba Pteridis Multifidae extract.Among the figure, chromatographic peak 1,2 (retention time was respectively 11.7,12.8 minutes) be followed successively by luteolin-7-O-β-D-glucoside, apigenin-7-O-beta-D-glucose-4 '-the O-alpha-L-rhamnoside.
The specific embodiment
Herba Pteridis Multifidae extract of the present invention is by the represented method manufacturing of following embodiment, and involved method is the technological means that those skilled in the art can grasp and use.But following examples must not be interpreted as the restriction to claim of the present invention of going up in all senses.
Embodiment 1: the preparation of Herba Pteridis Multifidae extract
This seminar has carried out systematic study to the macroporous resin process for refining of total flavone of phoenix-tail fern; Research contents comprises static adsorptive method, dynamic adsorption method evaluation screening different resins kind; Preferred AB-8 resin is carried out adsorption isotherm, saturated absorption leakage plot, gone up optimization investigations such as appearance concentration, condition of gradient elution, flow velocity, post blade diameter length ratio, obtained total flavone of phoenix-tail fern effective site.Main processes is following:
Herba Pteridis Multifidae medical material 20kg, with 70% alcohol reflux secondary, each 1.5 hours; Merge extractive liquid, is evaporated to 20L, adds 20L water hold over night; Filter, solution is splined in the AB-8 resin column of having handled well, and water, 20% ethanol, 70%, each 3BV of 95% ethanol carry out gradient elution respectively; 70% ethanol elution position obtains Herba Pteridis Multifidae extract (PM-F1) yellow powder 160.0g, yield 0.8% through concentrating under reduced pressure, drying.
The HPLC method is measured index component content among the PM-F1: adopt luteolin-7-O-β-D-glucoside (1), apigenin-7-O-beta-D-glucose-4 '-O-alpha-L-rhamnoside (2) self-control reference substance, measure index component content in the raw material.Chromatographic condition: 20% acetonitrile-(0.1% acetic acid-water) is the mobile phase isocratic elution, detects wavelength 340nm, 30 ℃ of column temperatures.Analysis result: the content that records chemical compound 1,2 among the PM-F1 is respectively 9.8%, 12.5%, the two summation 22.3%.
General flavone content in the colorimetric method for determining compositions: precision takes by weighing the about 5.0mg of the control substance of Rutin that is dried to constant weight, and methanol constant volume is to 25.0mL.Pipette above-mentioned solution 0,0.3,0.6,0.9,1.2,1.5,1.8,2.1mL respectively, place the 10mL volumetric flask, add water and mend, add 5% sodium nitrite 0.3mL, left standstill 6 minutes to 5mL; Add 10% aluminum nitrate 0.3mL, left standstill 6 minutes; Add 4% sodium hydroxide 2mL, add water and be settled to 10mL, survey solution absorbance A after 15 minutes in the 500nm place.Carry out linear regression with A and rutin content, the gained equation is A=1.07m+0.0095 (r
2=0.9995), range of linearity 0.129-0.903 μ g.It is an amount of to get test article, is contrast with the rutin, and general flavone content is 56.1% in the mensuration sample.
The HPLC collection of illustrative plates of Herba Pteridis Multifidae extract sample is referring to accompanying drawing.
Experimental example 1: the antiinflammatory action test of Herba Pteridis Multifidae extract
Get 40 of 20-25g mices, be divided into Herba Pteridis Multifidae ethanol extract (four groups of 12g crude drug/kg), Herba Pteridis Multifidae extract (300mg/kg) group, matched group and model group, one week of perfusion in advance.Last perfusion evenly was applied to mouse right ear with xylene 25 microlitres after 2 hours, put to death mice after half an hour, with diameter 6mm card punch, got the left and right sides ear same area of mice, weighed with analytical balance.It is the swelling degree that the auris dextra that takes off deducts left ear weight, calculates the average and the standard deviation of matched group and administration group, t check comparable group differences significance.Obtain inhibitory rate of intumesce by following formula:
Inhibitory rate of intumesce (%)=[the average swelling degree of the average swelling degree/model group of 1-administration group] * 100%
The result: (12g crude drug/kg), the acutely inflamed inhibitory rate of intumesce of Herba Pteridis Multifidae extract (300mg/kg) xylol induced mice auricle are respectively 57.8,51.3 (%) to the Herba Pteridis Multifidae ethanol extract; Compare no significant difference (P＜0.5) between two groups, show that the two all has certain inhibitory action.
Experimental example 2: the resistance prostatitis effect test of Herba Pteridis Multifidae extract
Select 90 of body weight 20～25g male mices; Be divided into normal group, model group, Herba Pteridis Multifidae ethanol extract group (totally 6 groups of 12g crude drugs/kg), Herba Pteridis Multifidae extract group (300mg/kg, 150mg/kg), normal saline matched group at random; Normal control group subcutaneous injection ethyl oleate 5ml/kg/d; The whole lumbar injection DPT vaccine of all the other mices 0.1ml; Multiple intradermal injections rat prostate albumen purification liquid and complete Freund's adjuvant (ratio is 1: 1 a suspension) 0.4ml is respectively at 0,30d carries out 2 injections.Behind the successive administration 30 days, put to death and respectively organize mice, inspection prostate pathology situation of change.
The result: 30 days mice produces the pathological manifestations of chronic inflammatory disease in various degree after the modeling; (lymphocyte, the plasma cell that soak in 12g crude drug/kg), the former prostatitis of Herba Pteridis Multifidae extract group (300mg/kg, the 150mg/kg) sex organization all reduce Herba Pteridis Multifidae ethanol extract group, show that Herba Pteridis Multifidae extract has the resistance prostatitis effect.
Experimental example 3: the inhibition prostatic hyperplasia effect test of Herba Pteridis Multifidae extract
Select 105 of body weight 20～25g male mices; Be divided into normal group, model group, Herba Pteridis Multifidae ethanol extract group (totally 7 groups of 12g crude drug/kg), Herba Pteridis Multifidae extract group (300mg/kg, 150mg/kg), proscar matched group and normal saline matched groups at random; Normal control group subcutaneous injection ethyl oleate 5ml/kg/d, the whole subcutaneous injection Testosterone Propionate of all the other mices 5mg/kg/d, successive administration is after 21 days; Put to death the matched group and the third testis model group mice, inspection prostatic hyperplasia situation; The administration group continued to irritate stomach normal saline, Herba Pteridis Multifidae preparation and proscar respectively continuous 30 days, every day 1 time, behind the last administration 24h, cutd open the prostata tissue pathological changes situation of each mice of inspection.
The result: normal control group pathology section examination prostata tissue, glandular epithelium is the monolayer column, monokaryon, ellipse is positioned at basilar part; Lumen of gland size basically identical, intracavity does not have or has a little secretions.The model group glandular epithelium fades to high column, and cell is arranged closely, and the part glandular epithelium is papillary hyperplasia, visible 2～3 the oval forming cores of individual cells.Lumen of gland is intensive, and is not of uniform size, and the chamber obviously enlarges, and the luminal sectetion thing significantly increases, and prostatic hyperplasia is remarkable.Herba Pteridis Multifidae ethanol extract group (12g crude drug/kg), Herba Pteridis Multifidae extract group (300mg/kg, 150mg/kg), the administration of proscar matched group after 30 days the pathology section examination prostatic hyperplasia alleviate.
Claims (10)
1. Herba Pteridis Multifidae extract, it is characterized in that containing in this extract apigenin-7-O-beta-D-glucose-4 '-O-alpha-L-rhamnoside and luteolin-7-O-β-D-glucoside, the method for preparing of said Herba Pteridis Multifidae extract is following:
(1) choose Herba Pteridis Multifidae platymiscium medical material, adopt water or alcohol-water mixed solvent to extract, the simmer down to concentrated solution adds the suitable quantity of water dilution, leaves standstill under the certain way 6-24 hour, filters, and gets Herba Pteridis Multifidae solution;
(2) by (1) gained Herba Pteridis Multifidae solution, adopt the good macroporous resin of pretreatment to adsorb, with washing, reuse alcohol-water mixed solvent is pressed 10-30%, 50-95% ethanol gradient elution earlier, collects 50-95% ethanol elution position eluent, concentrates, and drying promptly gets.
2. according to the method for preparing of the said Herba Pteridis Multifidae extract of claim 1, it is characterized in that selected Herba Pteridis Multifidae platymiscium is Herba Pteridis Multifidae (Pteris multifida) in its preparation methods steps (1).
3. according to the method for preparing of the said Herba Pteridis Multifidae extract of claim 1, it is characterized in that adding in its preparation methods steps (1) suitable quantity of water for by 1-5 times of medical material dry weight basis, the said mode of leaving standstill is room temperature or cold preservation, the preferred 8-16 of time of repose hour.
4. according to the method for preparing of the said Herba Pteridis Multifidae extract of claim 1, it is characterized in that the preferred low pole macroporous resin of macroporous resin described in its preparation methods steps (2), said alcohol-water mixed solvent is preferably pressed 15-25%, 60-75% ethanol gradient elution.
5. according to the said Herba Pteridis Multifidae extract of claim 1 to 4, it is characterized in that containing in this extract apigenin-7-O-beta-D-glucose-4 '-O-alpha-L-rhamnoside and luteolin-7-O-β-D-glucoside, the two total content is greater than 20%.
6. according to the said Herba Pteridis Multifidae extract of claim 5, it is characterized in that also containing in this extract luteolin-7-O-β-D-glucoside, apigenin-7-O-beta-D-glucoside, apigenin-3 '-more than at least a in the composition such as O-β-D-glucoside, apigenin, luteolin.General flavone content is greater than 50% in the said extract.
7. according to the application of the said Herba Pteridis Multifidae extract of claim 1 in food and medicine.
8. according to the application of the said Herba Pteridis Multifidae extract of claim 7 in food and medicine, be characterised in that said composition has antiinflammatory action.
9. according to the application of the said Herba Pteridis Multifidae extract of claim 7 in food and medicine, be characterised in that said composition has the resistance prostatitis effect.
10. according to the application of the said Herba Pteridis Multifidae extract of claim 7 in food and medicine, be characterised in that said composition has the effect of the prostatic hyperplasia of inhibition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100669854A CN102688261A (en) | 2011-03-21 | 2011-03-21 | Pteris multifida extract, preparation method thereof and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100669854A CN102688261A (en) | 2011-03-21 | 2011-03-21 | Pteris multifida extract, preparation method thereof and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102688261A true CN102688261A (en) | 2012-09-26 |
Family
ID=46854106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100669854A Pending CN102688261A (en) | 2011-03-21 | 2011-03-21 | Pteris multifida extract, preparation method thereof and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102688261A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104381794A (en) * | 2014-09-09 | 2015-03-04 | 盘县滑石智盛种植农民专业合作社 | Making method for Pteris multifida seed fried flour |
| CN106637456A (en) * | 2015-07-24 | 2017-05-10 | 众地家纺有限公司 | Antibacterial, deodorant and efficient deodorizing cellulose fibers and preparation method thereof |
| CN108395461A (en) * | 2017-02-07 | 2018-08-14 | 浙江康恩贝制药股份有限公司 | 7,4 '-O- β-D-Glucose morin glycosides and its preparation and its application in preparing anti-inflammatory drug |
| CN108524629A (en) * | 2018-05-25 | 2018-09-14 | 佛山汇沐化学科技有限公司 | A kind of hemostasia and dissipation blood stasis cream and preparation method thereof |
| CN112973173A (en) * | 2019-12-18 | 2021-06-18 | 中国科学院地理科学与资源研究所 | Resource utilization method of super-enriched plant biomass |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555869A (en) * | 2004-01-05 | 2004-12-22 | 玄振玉 | Preparation technology and use of Chinese herbal medicine phoenix-tail fern |
| CN1837226A (en) * | 2005-03-23 | 2006-09-27 | 中国科学院上海药物研究所 | Separation of medical derivatives from phoenix-tail fern and use thereof |
-
2011
- 2011-03-21 CN CN2011100669854A patent/CN102688261A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555869A (en) * | 2004-01-05 | 2004-12-22 | 玄振玉 | Preparation technology and use of Chinese herbal medicine phoenix-tail fern |
| CN1837226A (en) * | 2005-03-23 | 2006-09-27 | 中国科学院上海药物研究所 | Separation of medical derivatives from phoenix-tail fern and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 秦波等: "凤尾草的化学成分及其对体外大鼠前列腺上皮细胞增生的抑制效应", 《中国天然药物》, vol. 4, no. 6, 30 November 2006 (2006-11-30), pages 428 - 431 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104381794A (en) * | 2014-09-09 | 2015-03-04 | 盘县滑石智盛种植农民专业合作社 | Making method for Pteris multifida seed fried flour |
| CN106637456A (en) * | 2015-07-24 | 2017-05-10 | 众地家纺有限公司 | Antibacterial, deodorant and efficient deodorizing cellulose fibers and preparation method thereof |
| CN108395461A (en) * | 2017-02-07 | 2018-08-14 | 浙江康恩贝制药股份有限公司 | 7,4 '-O- β-D-Glucose morin glycosides and its preparation and its application in preparing anti-inflammatory drug |
| CN108395461B (en) * | 2017-02-07 | 2022-01-07 | 浙江康恩贝制药股份有限公司 | 7, 4' -O-beta-D-glucose morin glycoside, preparation thereof and application thereof in preparing anti-inflammatory drugs |
| CN108524629A (en) * | 2018-05-25 | 2018-09-14 | 佛山汇沐化学科技有限公司 | A kind of hemostasia and dissipation blood stasis cream and preparation method thereof |
| CN112973173A (en) * | 2019-12-18 | 2021-06-18 | 中国科学院地理科学与资源研究所 | Resource utilization method of super-enriched plant biomass |
| CN112973173B (en) * | 2019-12-18 | 2022-01-28 | 中国科学院地理科学与资源研究所 | Resource utilization method of super-enriched plant biomass |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography | |
| Zhou et al. | Separation and purification of α-glucosidase inhibitors from Polygonatum odoratum by stepwise high-speed counter-current chromatography combined with Sephadex LH-20 chromatography target-guided by ultrafiltration–HPLC screening | |
| CN102976909B (en) | Method for extracting and purifying 6-gingerol from ginger | |
| CN109364119A (en) | Preparation has the method and application of the total triterpene of hypoglycemic effect from Qingqian Willow leaf | |
| CN103145677B (en) | Method for separating active ingredients from aquilaria sinensis lamina by utilizing high-speed countercurrent chromatography | |
| CN102688261A (en) | Pteris multifida extract, preparation method thereof and use thereof | |
| CN105859803B (en) | A kind of preparation method of galloyl glucose | |
| CN103819445A (en) | Method for preparing two neo-pentenyl flavonoid compounds with hypolipidemic activity in fructus podophylli | |
| Dang et al. | Target separation of flavonoids from Saxifraga tangutica using two‐dimensional hydrophilic interaction chromatography/reversed‐phase liquid chromatography | |
| Peng et al. | Isolation and purification of clemastanin B and indigoticoside A from Radix Isatidis by high-speed counter-current chromatography | |
| Zhao et al. | Ultra‐high‐pressure‐assisted extraction of wedelolactone and isodemethylwedelolactone from Ecliptae Herba and purification by high‐speed counter‐current chromatography | |
| CN103113433B (en) | A kind of method extracting Oleuropein from Syringa pubescens | |
| Wang et al. | An Efficient Strategy Based on Liquid–Liquid Extraction With Acid Condition and HSCCC for Rapid Enrichment and Preparative Separation of Three Caffeoylquinic Acid Isomers From Mulberry Leaves | |
| Shi et al. | Preparative isolation and purification of two flavonoid glycosides from Taraxacum mongolicum by high-speed counter-current chromatography | |
| CN107365285A (en) | Ring neolignan and its production and use | |
| CA2982200A1 (en) | Phillygenin glucuronic acid derivative as well as preparation method and application thereof | |
| CN101234147A (en) | Method of preparing total flavones of tropaeolum for injections | |
| Liang et al. | Separation and purification of two minor compounds from Radix isatidis by integrative MPLC and HSCCC with preparative HPLC | |
| CN109010409B (en) | Extraction and purification process and content detection method of total flavonoids in herminium leaves | |
| CN109824643B (en) | Method for extracting fisetin from phyllanthus emblica | |
| CN107721857A (en) | A kind of method that high-purity chlorogenic acid is prepared from Gynura procumbens (Lour.) Merr | |
| CN102260152A (en) | Preparation method and medicinal application of shogaol extract | |
| Wu et al. | Simple and efficient preparation of 3, 6′-disinapoylsucrose from Polygalae Radix via column chromatographic extraction and reversed-phase flash chromatography | |
| Peng et al. | A comparative study of chromatographic methods for separating chemical compounds from Spiranthes australis (R. Brown) Lindl roots | |
| CN113527323A (en) | Method for extracting phenolic compounds from tung tree |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120926 |